Novel 1,4,5,6-tetrahydrocyclopenta[d]imidazole-5-carboxamide-based JNK3 inhibitors: Design, synthesis, molecular docking, and therapeutic potential in neurodegenerative diseases

Discovery of a Potent and Selective JNK3 Inhibitor with Neuroprotective Effect Against Amyloid β-Induced Neurotoxicity in Primary Rat Neurons

(2021) Joonhong Jun et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Discovery of 1-Pyrimidinyl-2-Aryl-4,6-Dihydropyrrolo [3,4-d]Imidazole-5(1H)-Carboxamide as a Novel JNK Inhibitor

(2020) Miyoung Jang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia

(2020) Howard A. Fink et al.   ANNALS OF INTERNAL MEDICINE

Discovery of 3-alkyl-5-aryl-1-pyrimidyl-1H-pyrazole derivatives as a novel selective inhibitor scaffold of JNK3

(2019) Youri Oh et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain

(2016) Luke R. Odell et al.   JOURNAL OF MEDICINAL CHEMISTRY

c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer’s Disease

(2016) Ramon Yarza et al.   Frontiers in Pharmacology

Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1 H -benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects

(2013) Mi-hyun Kim et al.   BIOORGANIC & MEDICINAL CHEMISTRY

JNK3 Perpetuates Metabolic Stress Induced by Aβ Peptides

(2012) Sung Ok Yoon et al.   NEURON

Specific activities of individual c-Jun N-terminal kinases in the brain

(2009) W. Haeusgen et al.   NEUROSCIENCE